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Abstract Purpose: Patients with
sepsis—after surviving the initial
hyperinﬂammatory phase—display
features consistent with immunosup-
pression, including
hyporesponsiveness of immunocom-
petent cells to bacterial agents.
Immunosuppression is thought to be
facilitated by negative regulators of
toll-like receptors, including mem-
brane-bound ST2. We investigated
the release of soluble ST2 (sST2), a
decoy receptor that inhibits mem-
brane-bound ST2 signaling, during
sepsis. Methods: The study popula-
tion comprised 95 patients with
severe sepsis admitted to one of two
intensive care units (ICUs) at the day
the diagnosis of severe sepsis was
made. Blood was obtained daily from
admission (day 0) until day 7 and
ﬁnally at day 14. Twenty-four healthy
subjects served as controls. sST2 and
cytokines were measured in serum.
Results: Mortality among patients
was 34% in the ICU and 45% in the
hospital. On admission, sepsis
patients had higher sST2 levels
[10,989 (7,871–15,342) pg/ml,
geometric mean (95% conﬁdence
interval, CI)] than controls [55 (20–
145) pg/ml, P\0.0001]. Serum
sST2 remained elevated in patients
from day 0 to 14 and correlated with
disease severity scores (P\0.001)
and cytokine levels on day 0 and
during course of disease
(P\0.0001). Nonsurvivors
displayed elevated sST2 levels
compared with survivors of the
intensive care unit (P\0.0001).
Conclusions: Sepsis results in sus-
tained elevation of serum sST2 levels,
which correlates with disease severity
and mortality.
Keywords ST2  Sepsis  Innate
immune response  Cytokines
Introduction
Sepsis is a major health problem which afﬂicts approxi-
mately 750,000 patients in the USA each year, associated
with mortality rates of 20–50% [1]. In the past decade it
has become clear that patients with severe sepsis—after
an initial hyperinﬂammatory phase—become immuno-
suppressed. Indeed, patients with sepsis display features
consistent with immunosuppression, including loss of
delayed hypersensitivity, inability to clear infection, and
predisposition to nosocomial infections. Clear evidence of
immunosuppression in sepsis comes from studies showing
hyporesponsiveness of immunocompetent cells to bacte-
rial agents [2–5]. Toll-like receptors (TLRs) are essential
for early detection of pathogens [6, 7], but can cause
excessive inﬂammation when their signaling activity
remains uncontrolled. To avoid detrimental inﬂammatory
responses TLR signaling is regulated by—among other
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interleukin-1 receptor-associated kinase-M, and ST2,
which have been suggested to play an important role
during the immunosuppressive state in severe sepsis [8–
10].
The st2 gene produces a soluble secreted form (sST2)
and a transmembrane form (ST2L) and is expressed in
several cells, including Th2 cells [11], mast cells [12],
and macrophages [13]. ST2L serves an important nega-
tive regulatory function for TLR signaling, as illustrated
by the fact that mice lacking ST2L are unable to develop
endotoxin tolerance [10]. Recently it has become clear
that interleukin (IL)-33 can bind to ST2L, thereby trig-
gering Th2-associated responses [14]. Soluble ST2,
which is mainly secreted by ﬁbroblasts [15], has been
suggested to act as a decoy receptor by binding IL-33,
thereby inhibiting signaling by ST2L [16, 17]. Previ-
ously it has been shown that soluble ST2 concentrations
are elevated in sera of patients with various immune
disorders and patients suffering from myocardial
infarction [18–23]. The functional role of soluble ST2
in vivo has not been fully elucidated. Mouse studies
have revealed that administration of a recombinant sol-
uble ST2-Fc fusion protein or a soluble ST2 vector
reduces inﬂammation and lethality in hepatic and
intestinal ischemia/reperfusion injury [24, 25] and
attenuates inﬂammatory responses in allergic lung
inﬂammation [26, 27].
Considering that ST2 possibly contributes to the
regulation of the immune response during severe
inﬂammation, we hypothesized that soluble ST2 levels
would be elevated in patients with sepsis and possibly
correlate with disease outcome. Therefore, we here per-
formed an explorative study to determine the extent of
soluble ST2 release over time in patients with severe
sepsis and its correlation with disease severity and
mortality.
Materials and methods
Patients and design
This study was approved by the scientiﬁc and ethics
committees of the St. Luc University Hospital (Brussels,
Belgium) and the St. Pierre’s Hospital (Ottignies, Bel-
gium). Written informed consent was obtained from all
subjects or their relatives. The study population com-
prised 95 patients with severe sepsis, deﬁned as a known
or suspected infection plus a systemic inﬂammatory
response syndrome, and failure of at least one organ [28];
these patients were admitted to the intensive care unit
(ICU) of either St. Luc University Hospital (n = 59) or
St. Pierre’s Hospital (n = 36) at the day severe sepsis was
diagnosed, and blood in a dry tube was obtained each day
starting at inclusion (day 0) until day 7 and ﬁnally at
day 14. After centrifugation, serum was then stored at
-70C until analysis. In the ICUs of both hospitals sepsis
was treated according to the surviving sepsis guidelines
[29]; as such no major treatment differences existed
between the two ICUs. A subgroup of this study popu-
lation was used previously to describe the release of high
mobility group box 1 in sepsis patients (n = 51) [30]. A
total of 24 healthy subjects, consisting of a combination
of healthy elderly from a nearby old people’s home and
healthy colleagues from the laboratory, served as controls.
Measurements and assays
Data were collected prospectively from patient records,
patient data management system (at the ICU), and hos-
pital information system. The following variables were
collected when appropriate: date of birth/death, sex, acute
physiology and chronic health evaluation (APACHE) II
and sepsis-related organ failure assessment (SOFA)
scores, organ dysfunction (both deﬁned according to the
1992 American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference [31]),
length of intensive care and hospital stay, blood culture
results, culture results of focus of infection, date of death,
body temperature, and level of C-reactive protein (CRP).
Analysis of serum samples was performed after patient
recruitment had been completed. Soluble ST2 was mea-
sured by commercially available enzyme-linked
immunosorbent assay (ELISA; R&D Systems, Minneap-
olis, MN; detection limit 780 pg/ml) according to the
instructions of the manufacturer. Tumor necrosis factor
(TNF)-a, IL-1b, IL-6, IL-8, IL-10, and IL-12p70 were
determined using a cytometric beads array multiplex
assay (BD Biosciences, San Jose, CA) according to the
instructions of the manufacturer. Detection limit was
2.5 pg/mL for all six cytokines measured.
Statistical analysis
Continuous patient characteristics were tested for normal
distribution using the Shapiro–Wilk test (W[0.90) and
are presented as mean ± standard deviation or median
with 25th and 75th percentile where appropriate. Cate-
gorical variables are presented as number and percentage.
Soluble ST2 and cytokine levels were right-skewed, and
log-transformed to obtain a normal distribution. These
variables are presented as geometric mean with 95%
conﬁdence interval (95% CI). Correlations between dif-
ferent variables are expressed as Pearson or Spearman
correlation coefﬁcients, where appropriate. Values for
patients at different time points and baseline values in the
control group were compared using the independent t test
(with correction for unequal variances, if necessary).
631Differences between sepsis groups and between survivors
and nonsurvivors of ICU or hospital stay were analyzed
using a linear mixed model with rank-transformed soluble
ST2 and cytokine values because of unequal variances at
the different time points. In case of an overall signiﬁcant
difference, post hoc tests were performed at the individ-
ual time points. All these analyses were carried out by
using SPSS (version 14; SPSS, Chicago, IL). To account
for multiple testing, P values\0.001 were considered
statistically signiﬁcant.
Results
Sepsis results in elevated serum soluble ST2 levels
irrespective of source of infection
The demographic and clinical characteristics of patients
with severe sepsis and healthy controls are presented in
Table 1. In total, 95 patients were included, with
mortality of 34% in the ICU and overall in-hospital
mortality of 45%. The primary sources of infection
were the lung [in 49 patients, 52%; community-
acquired pneumonia (CAP)], the abdomen (in 24
patients, 25%; peritonitis), and the urinary tract (in 19
patients, 20%; UTI). Compared with 24 healthy con-
trols (66 ± 22 years, mean ± SD; 50% male), septic
patients (66 ± 14 years, mean ± SD; 57% male) dis-
played elevated circulating levels of soluble ST2
starting on day 0 with a peak at day 1. Thereafter
soluble ST2 concentrations decreased again, but were
not yet normalized on day 14 compared with controls
(Fig. 1a). No statistical difference in increase of soluble
ST2 was seen when patients were stratiﬁed by sepsis
due to pneumonia, peritonitis, or urinary tract infection
(Fig. 1b, c, d).
Soluble ST2 levels correlate with disease severity
on day of onset
Soluble ST2 levels in serum were signiﬁcantly correlated
with both APACHE II and SOFA scores on day of onset
(day 0; Table 2). Moreover, soluble ST2 levels correlated
with presence of a positive blood culture. Body temper-
ature and C-reactive protein measured on day of onset did
not correlate with soluble ST2 levels. Additionally, sol-
uble ST2 levels did not correlate with length of ICU stay.
Elevation of soluble ST2 levels in nonsurviving septic
patients
Soluble ST2 levels were higher in patients who died in the
ICU (n = 32) than in patients who left the ICU alive
(n = 63); this difference between ICU survivors and
nonsurvivors was sustained until day 14 (Fig. 2a). In this
analysis we compared ICU survivors and nonsurvivors
since cause of death in patients who died in the hospital
after ICU discharge was mostly unrelated to sepsis.
Although soluble ST2 levels between overall hospital
survivors (n = 52) and overall nonsurvivors (n = 43)
were signiﬁcantly different (Fig. 2b), it appeared that
soluble ST2 levels of patients who died in the hospital
after ICU discharge (n = 11) were lower than those of
patients who died in the ICU (n = 32) (Fig. 2c).
Soluble ST2 levels correlate with cytokine levels
in serum of septic patients
To investigate whether soluble ST2 levels are correlated
with circulating cytokine levels in patients with severe
sepsis, we measured the serum concentrations of TNF-a,
IL-6, IL-8, IL-10, and IL-12p70 (Table 3). TNF-a, IL-1b,
Table 1 Patient characteristics
Characteristics Patients with
severe sepsis
(all) (n = 95)
Patients with sepsis
due to peritonitis
[n = 24 (25)]
Patients with sepsis
due to pneumonia
[n = 49 (52)]
Patients with sepsis
due to UTI
[n = 19 (20)]
Patients with
sepsis due to
other [n = 3 (3)]
Control
population
(n = 24)
Age (years) 66 ± 14 59 ± 15 68 ± 13 71 ± 10 60 ± 24 66 ± 22
Male sex 60 (57) 17 (71) 32 (65) 11 (58) 0 (0) 12 (50)
APACHE II 27 ± 92 8 ± 10 25 ± 82 9 ± 82 9 ± 15 NA
SOFA score 10 ± 51 1 ± 49 ± 51 1 ± 51 3 ± 7N A
ICU stay (days) 10 (5–22) 15 (6–29) 10 (5–21) 7 (2–22) 6 (4–6) NA
Pos. blood culture 45 (47) 13 (54) 17 (35) 14 (74) 1 (33) NA
Pos. culture of
infectious focus
81 (85) 20 (83) 40 (82) 19 (100) 2 (67) NA
Mortality ICU 32 (34) 9 (38) 16 (33) 6 (32) 1 (33) NA
Mortality overall 43 (45) 12 (50) 23 (47) 7 (37) 1 (33) NA
UTI urinary tract infection, APACHE acute physiology and chronic
health evaluation, SOFA sepsis-related organ failure assessment,
ICU intensive care unit, NA not applicable
Data are mean ± SD, median (25–75% interquartile range) or no.
(%) when appropriate
632and IL-12p70 levels were either very low or undetectable
in patients and not signiﬁcantly different from in healthy
controls (data not shown). Serum IL-6, IL-8, and IL-10
concentrations were elevated in sepsis patients at all time
points compared with controls (Table 3). Soluble ST2
levels and levels of cytokines IL-6, IL-8, and IL-10 were
signiﬁcantly correlated at day of onset (Table 4). During
the course of disease this correlation became less strong
(Table 4). Since correlation between soluble ST2 and
cytokine levels became less strong during the course of
disease than on day of onset (Table 4), we were interested
in investigating cytokine levels in ICU survivors versus
nonsurvivors (Fig. 3). Although overall IL-6, IL-8, and
IL-10 levels were higher in patients who died in the ICU,
the differences between survivors and nonsurvivors were
only apparent during the ﬁrst several days after
admission.
Discussion
In light of the possible contribution of negative regulators
of TLRs to the immunosuppressed state in septic patients,
we were interested in investigating the extent of soluble
ST2 release over time in patients with severe sepsis. Our
ﬁndings demonstrate that sepsis results in sustained and
stable elevation of soluble ST2, irrespective of the source
of infection. Moreover, soluble ST2 levels correlate with
disease severity and mortality.
Previously, others have demonstrated elevated soluble
ST2 levels in serum of patients with various immune
disorders such as asthma, pulmonary ﬁbrosis, various
autoimmune diseases, and dengue virus infection [18–20,
32]. In addition, soluble ST2 levels have been described
to be elevated in patients with sepsis [21]. However, this
study, showing soluble ST2 serum levels at only one time
point (\48 h from time of diagnosis), was performed in a
limited number of patients (n = 15), which may explain
the failure to demonstrate correlations between soluble
ST2 and disease severity or mortality. The current study
extends these ﬁndings, not only by showing elevation of
soluble ST2 in a much larger population of septic patients
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Fig. 1 Soluble ST2 levels in serum of patients with severe sepsis.
Concentrations of soluble ST2 were measured in serum of patients
with severe sepsis (‘‘all sepsis,’’ a, n = 95) and subgroups of these
patients with different infectious sources: abdomen (b, n = 24),
lungs (c, n = 49), or urinary tract (d, n = 19), and from healthy
controls (n = 24). Data are geometric means with 95% conﬁdence
intervals. At each time point, sepsis patients had higher soluble ST2
levels than healthy controls (P\0.0001) (for reasons of clarity not
indicated in the ﬁgure)
Table 2 Correlation between soluble ST2 and clinical markers on
day of onset
Clinical markers Serum soluble ST2
rP value
APACHE II 0.45 0.0001
SOFA score 0.49 \0.0001
Pos. blood culture 0.45 0.001
Serum level CRP 0.12 0.41
ICU stay (days) -0.07 0.62
Body temperature 0.12 0.42
APACHE acute physiology and chronic health evaluation, SOFA
sepsis-related organ failure assessment
633stratiﬁed according to infection source, but also by pro-
viding information on soluble ST2 levels during the
course of sepsis and correlations with concurrently mea-
sured cytokine concentrations. Of note, the ﬁrst blood
sample was obtained on the day of ICU admission, which
was also the day the diagnosis of ‘‘severe sepsis’’ was
made. This does not exclude, however, that severe sepsis
was already present prior to admission, although given the
severity of this syndrome, it seems unlikely that this
would have occurred in many patients and/or for pro-
longed time periods. A second limitation of this study
could be that patients were recruited from two ICUs,
although both centers followed the surviving sepsis
guidelines [29].
Our ﬁnding that soluble ST2 serum levels were most
upregulated at day 1 from onset of disease is in line with
previous studies describing soluble ST2 levels during the
course of disease. Recently, patients infected with dengue
virus were found to have mildly elevated levels of soluble
ST2 with a peak on day 0 (day of onset) and day 1 [32];
however, soluble ST2 levels returned to normal within
2 weeks. Moreover, studies describing soluble ST2 levels
in patients suffering from myocardial infarction revealed
that soluble ST2 was upregulated at day 1, but returned to
normal levels after 3 days [22, 23, 33]. In contrast, our
results indicate that, relative to controls, soluble ST2
remained upregulated until 14 days after onset of sepsis.
In this respect it is interesting to note that release of sol-
uble ST2 in the circulation after myocardial infarction is
thought to result from mechanical stress on cardiomyo-
cytes [22]. Considering that soluble ST2 is produced by
ﬁbroblasts underneath the vascular endothelium, it is
tempting to speculate that soluble ST2 is only released into
the circulation upon disruption of the endothelial layer, in
which case soluble ST2 would be indicative of the extent
of tissueinjury. Thiswouldalso providean explanationfor
the difference in duration of elevated soluble ST2 levels in
various inﬂammatory processes. Additional research is
warranted to further investigate the exact source of soluble
ST2 during sepsis and other inﬂammatory diseases. In
ICU mortality 
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Fig. 2 Elevated soluble ST2 levels correlate with mortality.
Soluble ST2 levels in patients who left the ICU alive (n = 63;
open squares) versus patients who died in the ICU (n = 32; ﬁlled
squares)( a), in patients who left the hospital alive (n = 52; open
squares) versus patients who died in the hospital (n = 43; ﬁlled
squares)( b), and in patients who died in the ICU (n = 32; ﬁlled
squares) versus patients who died in the hospital after ICU
discharge (n = 11; open squares)( c). Data are geometric means
with 95% conﬁdence intervals. **P\0.001, ***P\0.0005
Table 3 Cytokine levels in patients with severe sepsis
Day IL-6 IL-8 IL-10
0 351 [211–584] 214 [125–364] 23 [13–40]
1 341 [220–529] 184 [121–279] 19 [12–28]
2 154 [104–229] 100 [71–143] 12 [8–16]
3 131 [79–217] 99 [66–148] 14 [10–20]
4 134 [87–207] 106 [73–155] 15 [10–21]
5 75 [53–106] 84 [61–116] 9 [7–11]
6 66 [41–105] 102 [68–153] 9 [7–12]
7 66 [45–96] 86 [63–118] 10 [8–13]
14 85 [48–151] 91 [52–158] 7 [5–10]
Control 4 [3–7] 13 [10–17] 2 [1–2]
Data are geometric means [95% CI] in pg/ml; P\0,0001 (using
independent t test) for all time points for all cytokines, when
compared with controls
Table 4 Correlations between soluble ST2 and cytokine levels in
patients with severe sepsis
Soluble ST2
Day 0 Day 0–14
rP value rP value
IL-6 0.39 0.006 0.48 \0.0001
IL-8 0.55 \0.0001 0.51 \0.0001
IL-10 0.48 0.0007 0.48 \0.0001
Values measured at day 0 and during the complete stay at the ICU
P values from linear mixed models
634addition, considering the association between ST2 and
dampening of the immune response [8], it would be of
considerable interest to examine a possible relationship
between soluble ST2 levels and the occurrence of sec-
ondary nosocomial infections.
Various studies have demonstrated associations
between risk of death and cytokine levels during sepsis
[34–39]. However, cytokines have a short circulating
half-life and their release primarily occurs early after
exposure to an infectious challenge. Moreover, the range
of cytokine levels from survivors and nonsurvivors often
overlap, making them of poor prognostic value [1].
Considering the abundant literature on the possible value
of circulating cytokines as prognostic indicators in sepsis
we wanted to compare our soluble ST2 data with con-
currently measured cytokine concentrations. Although
there were signiﬁcant differences in cytokine levels (IL-6,
IL-8, and IL-10) between survivors and nonsurvivors in
the current investigation, cytokine levels were especially
widely spread in nonsurvivors and tended to decrease
sharply after 5 days. In contrast, soluble ST2 levels of
nonsurvivors remained stably elevated until day 14
compared with survivors. This difference in course during
sepsis is further corroborated by the fact that correlations
between soluble ST2 levels and cytokine levels became
less strong during the course of disease when compared
with their correlations on the day of onset. Notably, serum
TNF-a and IL-1b levels were low or undetectable in the
current cohort of sepsis patients. Previous studies have
reported highly variable circulating levels of these two
proinﬂammatory cytokines, at least in part depending on
the assays used and the severity of sepsis [39]. Our
present data ﬁt into this extensive literature in that many
earlier studies have reported low TNF-a and IL-1b con-
centrations in the circulation of sepsis patients, which is in
accordance with the short circulating half-life of these
mediators [39].
Conclusions
We here establish that severe sepsis results in stable and
sustained elevation of serum soluble ST2 levels. More-
over, soluble ST2 levels correlate with disease severity
and mortality. Further investigations are warranted to
elucidate the function of soluble ST2 during the immune
response in septic patients.
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